Treatment of Bone Metastases of Breast Cancer With 177Lu-DOTA-IBA-Reference-Cited by-同舟云学术

Treatment of Bone Metastases of Breast Cancer With 177Lu-DOTA-IBA

Published:2024-03-25 Issue:7 Volume:49 Page:659-661
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Deng Jia,Yang Jian,Cheng Zixuan¹,Chen Yue

Affiliation:

1. Department of Ophthalmology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China.

Abstract

Abstract Bone metastasis of breast cancer often presents as osteolytic. 177Lu-DOTA-ibandronic acid (177Lu-DOTA-IBA) is a new radioactive drug for bone metastasis lesion. We report a case of recurrent intermittent pain due to bone metastasis, who demonstrated a satisfactory therapy response after 2 cycles of 177Lu-DOTA-IBA. In addition, the patient did not have any observable adverse effects.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference11 articles.

1. Lutetium177-labeled DOTA-ibandronate: a novel radiopharmaceutical for targeted treatment of bone metastases;Mol Pharm,2023

2. Safety and efficacy of 68Ga- or 177Lu-labeled DOTA-IBA as a novel theranostic radiopharmaceutical for bone metastases: a phase 0/I study;Clin Nucl Med,2023

3. Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA;Front Oncol,2022

4. Biodistribution and internal dosimetry of 68Ga-DOTA-IBA PET imaging for patients with bone metastases;Clin Nucl Med,2023

5. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets;Semin Cancer Biol,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidental Uptake of 68Ga-DOTA-IBA in Prostate Adenocarcinoma;Clinical Nuclear Medicine;2024-08-28